Eli Lilly (LLY) market share drops to 56% in India as generics flood
Published on · Source: cnbc.com
AI Summary
Summarized by AI from the source belowEli Lilly (LLY) saw its market share in India's GLP-1 weight-loss drug category decline to 56% in March from 61% in February, according to Pharmarack data. Meanwhile, Novo Nordisk (NVO) maintained a steady 25% market share despite the influx of generic semaglutide drugs following the expiration of its patent last month. The launch of 26 brands by 13 Indian generic companies is significantly impacting sales for Eli Lilly's higher-priced tirzepatide products. As generic options become more affordable, the competitive landscape for weight-loss treatment in India is changing rapidly, likely benefiting Novo Nordisk in the long run.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Eli Lilly and Company (LLY)
Eli Lilly is a major pharmaceutical company known for diabetes and obesity treatments and a broad drug pipeline.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier LLY news
- Senator Angus King Jr. Sells $1,000 to $15,000 in Autodesk (ADSK)
- Eli Lilly (LLY) Receives FDA Approval for Weight Loss Pill, Acquires Centessa
- Eli Lilly (LLY) Acquires Centessa for $7.8 Billion
- Eli Lilly (LLY) Stock Rating Reiterated After Obesity Drug Approval
- Eli Lilly (LLY) Obesity Pill Foundayo Receives FDA Approval
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
